Format

Send to

Choose Destination
BMJ Open. 2018 Feb 10;8(2):e019593. doi: 10.1136/bmjopen-2017-019593.

Sequelae of multidrug-resistant tuberculosis: protocol for a systematic review and meta-analysis.

Author information

1
Research School of Population Health, College of Health and Medicine, Australian National University, Canberra, Australia.
2
Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
3
Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, Queensland, Australia.
4
Global TB Programme, World Health Organization, Geneva, Switzerland.
5
Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden.
6
Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.

Abstract

INTRODUCTION:

The sequelae of multidrug-resistant tuberculosis (MDR-TB) are poorly understood and inconsistently reported. We will aim to assess the existing evidence for the clinical, psychological, social and economic sequelae of MDR-TB and to assess the health-related quality of life in patients with MDR-TB.

METHODS AND ANALYSIS:

We will perform a systematic review and meta-analysis of published studies reporting sequelae of MDR-TB. We will search PubMed, SCOPUS, ProQuest, Web of Science and PsychINFO databases up to 5 September 2017. MDR-TB sequelae will include any clinical, psychological, social and economic effects as well as health-related quality of life that occur after MDR-TB treatment or illness. Two researchers will screen the titles and abstracts of all citations identified in our search, extract data, and assess the scientific quality using standardised formats. Providing there is appropriate comparability in the studies, we will use a random-effects meta-analysis model to produce pooled estimates of MDR-TB sequelae from the included studies. We will stratify the analyses based on treatment regimen, comorbidities (such as HIV status and diabetes mellitus), previous TB treatment history and study setting.

ETHICS AND DISSEMINATION:

As this study will be based on published data, ethical approval is not required. The final report will be disseminated through publication in a peer-reviewed scientific journal and will also be presented at relevant conferences.

PROSPERO REGISTRATION NUMBER:

CRD42017073182.

KEYWORDS:

MDR-TB; meta-analysis; multidrug-resistant tuberculosis; protocol; sequelae; systematic review

PMID:
29440162
PMCID:
PMC5829942
DOI:
10.1136/bmjopen-2017-019593
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center